PT - JOURNAL ARTICLE AU - Christian Buchbender AU - Till A. Heusner AU - Thomas C. Lauenstein AU - Andreas Bockisch AU - Gerald Antoch TI - Oncologic PET/MRI, Part 2: Bone Tumors, Soft-Tissue Tumors, Melanoma, and Lymphoma AID - 10.2967/jnumed.112.109306 DP - 2012 Aug 01 TA - Journal of Nuclear Medicine PG - 1244--1252 VI - 53 IP - 8 4099 - http://jnm.snmjournals.org/content/53/8/1244.short 4100 - http://jnm.snmjournals.org/content/53/8/1244.full SO - J Nucl Med2012 Aug 01; 53 AB - With integrated whole-body PET/MRI, a novel metabolic–anatomic imaging technique recently has been introduced into clinical practice. This review addresses PET/MRI of bone tumors, soft-tissue sarcoma, melanoma, and lymphoma. If PET/MRI literature is not yet available for some types of tumors, potential indications are based on available PET/CT and MRI data. PET/MRI seems to be of benefit in T-staging of primary bone tumors and soft-tissue sarcomas. With regard to N-staging, PET/MRI can be considered similarly accurate to PET/CT when applied as a whole-body staging approach. M-staging will benefit from MRI accuracy in the brain, the liver, and bone.